GlassScriptPhysician profile
Joel B Landry
NPI 1982669719
$9,787.73
in general payments reported to CMS, 2019-2025
41 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,246 · 2020: $984 · 2021: $939 · 2022: $1,533 · 2023: $1,978 · 2024: $1,692 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,084.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,674.60 | 2019-2025 | |
| Lilly USA, LLC | $1,299.16 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,014.21 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,012.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $654.10 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $552.81 | 2020-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $402.60 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.17 | 2019-2023 | Synjardy, Jardiance |
| Astellas Pharma US INC | $317.59 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $294.12 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $222.44 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $216.59 | 2019-2025 | Eliquis, Camzyos |
| Biohaven Pharmaceutical Holding Company LTD. | $212.26 | 2022 | |
| Allergan, INC. | $186.39 | 2019-2020 | |
| Exact Sciences Corporation | $166.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Landry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.